In a laboratory in Dresden, researchers have discovered a way to steer cancer cells into new behavioral states—not by rewriting their genetic code, but by changing the material landscape around them. Dr. Ali Nadernezhad and his team at the Leibniz Institute for Polymer Research have developed engineered biomaterials that can guide pancreatic cancer organoids toward different cell states, a breakthrough that sidesteps the limitations and ethical complexities of genetic manipulation.
Understanding how cancer cells transition between different states has long been one of tumor biology's most pressing puzzles. Cells don't stay locked in place; they shift, adapt, and transform in ways that fuel progression and metastasis. Until now, most researchers trying to direct these transitions have relied on altering genes themselves. Nadernezhad's approach takes a fundamentally different path: by engineering the microenvironment that surrounds cancer cells, the team can influence how those cells behave without touching their DNA.
The research builds on patient-derived organoids—miniature tumor models grown from actual patient samples that faithfully preserve the architecture, complexity, and diversity of real cancers. These three-dimensional systems are far more representative of actual tumors than flat cell cultures, and they respond to their surroundings much as cancer cells do in the body. The key insight is that organoids are not locked into a fixed state; they can self-organize and transform in response to environmental signals.
Working in collaboration with Professor Daniel E. Stange from Universitätsklinikum Carl Gustav Carus Dresden, Nadernezhad's team created a data-driven platform to design biomaterials that could nudge organoids in specific directions. They engineered star-shaped polyethylene glycol hydrogels—synthetic scaffolds that mimic aspects of the tissue environment—and functionalized them with bioactive peptides. By systematically testing different formulations and carefully measuring how gene expression changed in response, they built a framework for predicting which material compositions would trigger which cellular transitions.
In their proof-of-concept study, published in Advanced Materials, the researchers demonstrated that they could push pancreatic cancer organoids toward an epithelial-to-mesenchymal transition, or EMT—a cellular program intimately linked to cancer progression and the ability of tumors to spread. This wasn't a theoretical achievement; it was a concrete demonstration that biomaterial design could be used as a dial to turn cell-state transitions up or down.
What makes this approach particularly promising is its non-genetic nature. Genetic therapies are powerful but slow, expensive, and carry risks. Engineering the microenvironment is faster, more reversible, and opens doors to applications that genetic approaches cannot easily reach. For cancer biology, this could mean new ways to study how tumors evolve and adapt. For regenerative medicine, it suggests we might guide cells toward healing states. For biomaterials themselves, it validates the principle that smart materials can be designed not just to support cells, but to instruct them.
The work also reflects a larger shift in how researchers think about cancer. Rather than viewing tumors as genetically determined entities locked in their fate, this research embraces the reality that cancer cells are responsive, plastic, and shaped by their environment. By understanding and engineering that environment, researchers may find new leverage points for intervention—not by fighting cancer's nature, but by understanding it more deeply.